Impact of telepharmacy during COVID-19 on patients’ outcome during COVID-19: a systematic literature review

Main Article Content

Dalal Salem Al-Dossari https://orcid.org/0000-0003-3279-248X
Yahya Ali Laghbi https://orcid.org/0000-0002-0832-3483
Abdullah Saud Almutairi https://orcid.org/0009-0002-2903-9569
Meshal Mohammad Alsupail https://orcid.org/0009-0008-6887-1191
Fuad Khulaif Alharbi https://orcid.org/0009-0009-1144-2959
Mohammed Hamdan Alharbi https://orcid.org/0009-0005-9378-8347
Saud Alotaibi https://orcid.org/0009-0007-0227-870X
Anam Farooq https://orcid.org/0000-0002-1131-2259
SHERAZ ALI https://orcid.org/0000-0001-9557-0345

Keywords

Abstract

Background: Coronavirus disease (COVID-19) continues to be a major global public health issue. COVID-19 is highly contagious, and numerous mitigation strategies have recently been implemented to prevent the spread of this disease. Pharmacists utilize telecommunication technology to provide patient care services, thus increasing patient access to pharmaceutical services. There was a scarcity of evidence regarding the impact of telepharmacy on patient outcomes during COVID-19. Therefore, the aim of this study was to summarize the available research evidence on the impact of telepharmacy on patient outcomes during COVID-19. Methods: A systematic literature search was conducted between January 2020 to September 2022 in Ovid MEDLINE, Ovid Embase, and Cochrane Central Register of Controlled Trials, using appropriate terms on telepharmacy, COVID-19, and patient outcomes. Only studies that investigated the impact of telepharmacy on patient outcomes during COVID-19 were included. A systematic literature search was conducted between January 2020 to September 2022 in Ovid MEDLINE, Ovid Embase, and Cochrane Central Register of Controlled Trials, using appropriate terms on telepharmacy, COVID-19, and patient outcomes. Only studies that investigated the impact of telepharmacy on patient outcomes during COVID-19 were included. Results: A total of three studies were included in the review. The telepharmacy services were offered via virtual anticoagulation clinic, retail community telepharmacy through information technology tools, and RxLive® telepharmacy program. All studies included in the review demonstrated that the provision of telepharmacy services during COVID-19 had an overall positive impact on the patient outcomes such as a reduction in the rates of hospitalisation and medication-related problems and maintaining the international normalized ratio values within the therapeutic range. Conclusion: This review provides evidence that telepharmacy services have been successful in improving patient outcomes during the COVID-19 pandemic, including reductions in medicines-related problems and hospitalization rates. As the pandemic continues, there is an urgent need to further expand telepharmacy services, using modern communication technologies such as televideo, especially for patients living in remote areas. There is a need to conduct further pre-post-intervention studies to address this gap.


 

Abstract 251 | PDF Downloads 164

References

1. Khachfe HH, Chahrour M, Sammouri J, et al. An Epidemiological Study on COVID-19: a rapidly spreading disease. Cureus. 2020;12(3):e7313. https://doi.org/10.7759/cureus.7313
2. Ghina Nadhifah Iftinan NW, Keri Lestar. Telepharmacy: A Potential Alternative Approach for Diabetic Patients During the COVID-19 Pandemic. Journal of Multidisciplinary Healthcare. 2011;14:2261-2273. https://doi.org/10.2147/JMDH.S325645
3. Ellen S. Koster DP, Marcel L, et al. COVID-19 epidemic on the provision of pharmaceutical care in community pharmacies.
Research in Social and Administrative Pharmacy. 2021;17(1):2002-2004. https://doi.org/10.1016/j.sapharm.2020.07.001
4. Health Resources & Services Administration. Office for the Advancement of Telehealth. Available online: https://www.hrsa. gov/rural-health/telehealth.
5. American Society of Health-Systems Pharmacists. ASHP Statement on Telepharmacy. Available online: https://www.ashp. org/-/media/assets/pharmacy-informaticist/docs/sopit-bp-telepharmacy-statement.ashx
6. Keeys C, Kalejaiye B, Skinner M, et al. Pharmacist-managed inpatient discharge medication reconciliation: a combined onsite and telepharmacy model. Am J Heal Pharm. 2014;71(24):2159-2166. https://doi.org/10.2146/ajhp130650
7. Koster ES, Philbert D, Bouvy ML. Impact of the COVID-19 epidemic on the provision of pharmaceutical care in community pharmacies. Research in Social and Administrative Pharmacy. 2021;17(1):2002-2004. https://doi.org/10.1016/j. sapharm.2020.07.001
8. Koster ES, Philbert D, Bouvy ML. Health literacy among pharmacy visitors in The Netherlands. Pharmacoepidemiol Drug Saf. 2015;24(7):716-721. https://doi.org/10.1002/pds.3803
9. Martin RD. Leveraging telecommuting pharmacists in the post-COVID-19 world. J Am Pharm Assoc (2003). 2020;60(6):e113-e115.
https://doi.org/10.1016/j.japh.2020.07.026
10. Le T, Toscani M, Colaizzi J. Telepharmacy: A New Paradigm for Our Profession. J Pharm Pract. 2020;33(2):176-182. https://doi. org/10.1177/0897190018791060
11. Liu S, Luo P, Tang M, et al. Providing pharmacy services during the coronavirus pandemic. Int J Clin Pharm. 2020;28(2):1-6.
https://doi.org/10.1007/s11096-020-01017-0
12. Di Cerbo A, Morales-Medina JC, Palmieri B, et al. Narrative review of telemedicine consultation in medical practice. Patient Prefer Adherence. 2015;9:65-75. https://doi.org/10.2147/PPA.S61617
13. Unni EJ, Patel K, Beazer IR, et al. Telepharmacy during COVID-19: A Scoping Review. Pharmacy (Basel). 2021;9(4):183. https:// doi.org/10.3390/pharmacy9040183
14. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097. https://doi.org/10.1371/journal.pmed.1000097
15. Al Ammari M, AlThiab K, Al Johani M. Tele-pharmacy Anticoagulation Clinic During COVID-19 Pandemic: Patient Outcomes. Front Pharmacol. 2021;12:652482. https://doi.org/10.3389/fphar.2021.652482
16. Osama M Ibrahim RMI, Ahmad Z Al Meslamani, Nadia Al Mazrouei. Role of telepharmacy in pharmacist counselling to coronavirus disease 2019 patients and medication dispensing errors. Journal of Telemedicine and Telecare. 2020;29(1):18-27.
https://doi.org/10.1177/1357633X20964347
17. Hefti E, Wei B, Engelen K. Access to Telepharmacy Services May Reduce Hospital Admissions in Outpatient Populations During the COVID-19 Pandemic. Telemedicine and e-Health. 2022;28(9):1324-31. https://doi.org/10.1089/tmj.2021.0420
18. Bond CA, Raehl CL. Clinical pharmacy services, pharmacy staffing, and adverse drug reactions in United States hospitals. Pharmacotherapy. 2006;26(6):735-747. https://doi.org/10.1592/phco.26.6.735
19. Tran RJC, Yamzon J, Stewart TL, et al. Effectiveness of Telepharmacy Versus Face-to-Face Anticoagulation Services in the Ambulatory Care Setting: A Systematic Review and Meta-analysis. Annals of Pharmacotherapy. 2020;55(9):1084-1095. https:// doi.org/10.1177/1060028020983539
20. Elbeddini A, Yeats A. Pharmacist intervention amid the coronavirus disease 2019 (COVID-19) pandemic: From direct patient care to telemedicine. J Pharm Policy Pract. 2020;13:23. https://doi.org/10.1186/s40545-020-00229-z
21. Mohammad I, Berlie HD, Lipari M, et al. Ambulatory care practice in the COVID-19 era: Redesigning clinical services and experiential learning. J Am Coll Clin Pharm. 2020;3(6):1129-1137. https://doi.org/10.1002/jac5.1276
22. Mohiuddin AK. Prospect of tele-pharmacists in COVID-19 pandemic situation in Bangladesh. J Biosci Biomed Eng. 2020;1.
https://doi.org/10.47485/2693-2504.1004
23. Kulatunga GG, Hewapathirana R, Marasinghe IRB, et al. A review of telehealth practices in Sri Lanka in the context of the COVID-19 pandemic. Sri Lanka J Biomed Inform. 2020;11(1):8-19. https://doi.org/10.4038/sljbmi.v11i1.8090
24. Elizabeth J, Unni KP, Beazer IR, et al. Telepharmacy during COVID-19: A Scoping Review. 2021;9(4):183. https://doi.org/10.3390/ pharmacy9040183

Most read articles by the same author(s)